Clinically important factors affecting platelet transfusion outcomes.
| . | 1-hour platelet increment (platelets/μL) . | 18- to 24-hour platelet increment (platelets/μL) . | Refractoriness (hazard ratio) . | Days-to-next transfusion . |
|---|---|---|---|---|
| *A clinically important change for 1-hour and 24-hour post-transfusion increments and days to next transfusion was considered to be a ≥20% difference (either an increased or a decreased response) from the overall responses observed in the trial. | ||||
| †For the hazard ratio, an increase of ≥2.0 was considered clinically important. | ||||
| ‡Value meets the criteria for a clinically important change. If a result is given but not noted with ‡, it is significantly different statistically but does not meet the clinically important criterion. If no value is listed (—), there was neither a clinically important nor statistically significant difference for the outcome measure. | ||||
| §The platelet increment was estimated to be 9300 platelets/μL less at 1 hour after transfusion for all study arms except UV-B. UV-B platelets were reduced by only 750 platelets/μL. The platelet increment was estimated to be 4000 platelets/μL less at 18 to 24 hours after transfusion for all arms. | ||||
| From Slichter SJ, et al. Blood. 2005;105:4106–4114.32 | ||||
| Factor | ||||
| Overall response | 24,900 | 12,000 | 1.75 | |
| Clinically important change | ≥ 5000* | ≥ 2400* | ≥ 2.0† | ≥ 0.35* |
| Improved Platelet Responses | ||||
| Splenectomy | +24,800‡ | +12,400‡ | — | — |
| ABO compatible | +4,600 | +6300‡ | — | — |
| Decreased Platelet Responses | ||||
| Lymphocytotoxic antibody-positive | −9300‡§ | −4000‡ | 3.48‡ | −0.36‡ |
| Females with ≥ 2 pregnancies, and males | −8900‡ | −5700‡ | 2.78‡ | −0.40‡ |
| Palpable spleen | −3500 | −4400‡ | — | −0.23 |
| Heparin | — | −3800‡ | 2.43‡ | −0.37‡ |
| Bleeding | −1700 | −3100‡ | 2.00‡ | −0.33 |
| Fever | −1600 | −2000 | 2.12‡ | −0.25 |
| Amphotericin | −2700 | −2500‡ | — | −0.28 |
| DIC | — | — | — | −0.40‡ |
| . | 1-hour platelet increment (platelets/μL) . | 18- to 24-hour platelet increment (platelets/μL) . | Refractoriness (hazard ratio) . | Days-to-next transfusion . |
|---|---|---|---|---|
| *A clinically important change for 1-hour and 24-hour post-transfusion increments and days to next transfusion was considered to be a ≥20% difference (either an increased or a decreased response) from the overall responses observed in the trial. | ||||
| †For the hazard ratio, an increase of ≥2.0 was considered clinically important. | ||||
| ‡Value meets the criteria for a clinically important change. If a result is given but not noted with ‡, it is significantly different statistically but does not meet the clinically important criterion. If no value is listed (—), there was neither a clinically important nor statistically significant difference for the outcome measure. | ||||
| §The platelet increment was estimated to be 9300 platelets/μL less at 1 hour after transfusion for all study arms except UV-B. UV-B platelets were reduced by only 750 platelets/μL. The platelet increment was estimated to be 4000 platelets/μL less at 18 to 24 hours after transfusion for all arms. | ||||
| From Slichter SJ, et al. Blood. 2005;105:4106–4114.32 | ||||
| Factor | ||||
| Overall response | 24,900 | 12,000 | 1.75 | |
| Clinically important change | ≥ 5000* | ≥ 2400* | ≥ 2.0† | ≥ 0.35* |
| Improved Platelet Responses | ||||
| Splenectomy | +24,800‡ | +12,400‡ | — | — |
| ABO compatible | +4,600 | +6300‡ | — | — |
| Decreased Platelet Responses | ||||
| Lymphocytotoxic antibody-positive | −9300‡§ | −4000‡ | 3.48‡ | −0.36‡ |
| Females with ≥ 2 pregnancies, and males | −8900‡ | −5700‡ | 2.78‡ | −0.40‡ |
| Palpable spleen | −3500 | −4400‡ | — | −0.23 |
| Heparin | — | −3800‡ | 2.43‡ | −0.37‡ |
| Bleeding | −1700 | −3100‡ | 2.00‡ | −0.33 |
| Fever | −1600 | −2000 | 2.12‡ | −0.25 |
| Amphotericin | −2700 | −2500‡ | — | −0.28 |
| DIC | — | — | — | −0.40‡ |